2.Generation of monoclonal antibodies reactive to human interleukin 2(IL 2).
Youn Mun HA ; Jun Hyung LEE ; Seung Min YOO ; Jeong Je CHO ; Soon Tae HO ; Jae Kyung PARK ; Sang Yun NAM
Journal of the Korean Society for Microbiology 1993;28(4):313-319
No abstract available.
Antibodies, Monoclonal*
;
Humans*
;
Interleukins*
3.Studies on the production and application of monoclonal antibodies against human gastrointestinal tumor cell lines(I).
Korean Journal of Immunology 1991;13(2):201-214
No abstract available.
Antibodies, Monoclonal*
;
Humans*
4.The role of monoclonal antibodies (Omalizumab) in the treatment of asthma
Journal of Medical and Pharmaceutical Information 2004;0(7):16-19
Immunoglobulin E (IgE) is important in pathogenesis of allergic asthma reaction. Thus, inhibiting the combination of IgE and receptors in the membrane of mastocytes and other effective cells is able to reduce the body responses with allergens and decrease symptoms of asthma attacks. Monoclonal antibodies (Omalizumab) are effective in inhibiting the combination of IgE and receptors. The use of monoclonal antibodies in asthma treatment opened a new strategy, and confirmed the important roles of immunoglobulins in pathogenesis of asthma
Antibodies, Monoclonal
;
Therapeutics
;
asthma
5.Characterization of monoclonal antibodies against human cytomegalovirus(HCMV) glycoprotein.
Eung Soo HWANG ; Ju Young SEOH ; Chung Gyu PARK ; Yoon Hoh KOOK ; Chang Yong CHA
Journal of the Korean Society for Microbiology 1992;27(6):545-553
No abstract available.
Antibodies, Monoclonal*
;
Glycoproteins*
;
Humans*
8.Histological study of the expanded skin using monoclonal antibodies.
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1992;19(2):167-172
No abstract available.
Antibodies, Monoclonal*
;
Skin*
9.Generation and Characterization of Anti - Human CTLA - 4 Monoclonal Antibodies.
Chang Yuil KANG ; Kwang Mi KIM
Korean Journal of Immunology 1997;19(4):447-454
No abstract available.
Antibodies, Monoclonal*
;
Humans*
10.Remission of Cap Polyposis Maintained for More Than Three Years after Infliximab Treatment.
Eun Sun KIM ; Yoon Tae JEEN ; Bora KEUM ; Yeon Seok SEO ; Hoon Jai CHUN ; Soon Ho UM ; Chang Duck KIM ; Ho Sang RYU
Gut and Liver 2009;3(4):325-328
Cap polyposis is a rare disorder with characteristic endoscopic and histological features; its etiology is still unknown, and no specific treatment has been established. We report a case of cap polyposis that improved remarkably after infliximab infusion and had no recurrence for 3 years.
Antibodies, Monoclonal
;
Recurrence
;
Infliximab
Result Analysis
Print
Save
E-mail